A guidance on diagnosis and management of hyperglycemia at COVID care facilities in India.

摘要: Abstract Background and aims Diabetes coronavirus disease 2019 (COVID-19) share a bidirectional relationship. Hyperglycemia occurring in the setting of either previously diagnosed or undiagnosed diabetes is known to be associated with poor outcomes. Here, we aim provide simple practical guidance on diagnosis management hyperglycemia admitted patients COVID-19. Methods The formulated based experience authors relevant literature subject searched using Pubmed. Results Every patient COVID care facility should investigated for combination tests including capillary blood glucose, fasting plasma glucose HbA1c. Oral lowering drugs can considered mild illness who have (pre-meal ≥180 mg/dl post-meal ≥250 mg/dl) no contraindication use these agents. All moderate-severe and/or greater severity initiated insulin therapy. aggressively screened managed receiving systemic glucocorticoids. Conclusion This document provides broad overview at facilities useful wide range healthcare personnel involved